The veterinary oncology market is projected to witness considerable growth during the forecast period on account of increasing regulatory approvals for veterinary oncology products. For instance, in 2018, Aratana Therapeutics obtained provisional clearance for its canine osteosarcoma vaccine from the U.S. Department of Agriculture’s Center for Veterinary Biologics.
The manufacturers are focused on undertaking acquisition strategies to expand their product portfolio and gain a competitive edge. For instance, in 2018, Zoetis acquired Abaxis, a firm focused on the growth, manufacturing, and distribution of diagnostic instruments for point-of-care veterinary services. Technological advancements in animal cancer treatment provide an impetus to the market growth. In 2018, AdvaVet, a subsidiary of Oasmia Pharmaceutical AB, developed an innovative technology, XR17, for formulating nanoparticles that make water-soluble to a single API or multiple APIs. This system increases solubility and guarantees safe animal administration of APIs.
Got questions about your regional growth of
Veterinary Oncology Market?
Just drop us a line or call on +1 646 480 7505
By Animal Type
By Cancer Type
" Crucial Insights The Report Provides:"
* Known and Unknown Adjacencies Influencing the Growth of Market
* Explorable Revenue Sources
* Customer Behaviour Analysis
* Target Partners
* Customized Geographical Data Based on Customers as well as Competitors
* Analysis of Market Size and CAGR between the Forecast PeriodsView Full Report Buy This Report Now